Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

The global lung cancer surgery market is projected to reach USD 1.48 billion in 2025, and is expected to expand further to ...

A meta-analysis of nearly 3.9 million participants shows people with allergies have significantly lower odds of developing ...

Scottish Liberal Democrats have today launched a petition which calls for the SNP government to roll out a full, nationwide ...

Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.

From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

The age-adjusted cancer death rate has fallen since the 1990s, with the world winning the so-called "war on cancer." ...

The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Doctors at Baylor College of Medicine have confirmed that the use of the portable Organ Care System (OCS), or "breathing lung ...

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.